ANLBIO, a biotechnology company developing gene therapies for neurodegenerative diseases, has selected Biovian Oy as a CDMO partner. The agreement covers process development for ANLBIO’s proprietary gene therapy vector, ANL-101, followed by 200 L scale production. This Adeno Associated Virus (AAV)-based product is prepared to be evaluated in clinical trials for the treatment of Alzheimer’s disease.
In detail, the agreement covers the GMP Cell Bank manufacturing, process and analytical development, and validation of product-specific analytical methods. The manufacturing part of the agreement covers upscaling of the process to working volume of hundreds of liters and subsequent drug product manufacture at Biovian’s facilities in Turku, Finland.
Hong Sung Moon, CEO of ANLBIO
We are very pleased that we have found a CDMO partner that can help us take this important project to the next level. Alzheimer’s disease is the most common cause of dementia. As the size of the population age 65 and older continues to increase, the number of people with Alzheimer’s or other dementias are growing. ANLBIO wants to address this need through the development and commercialization of innovative delivery platforms such as ANL-101.
Antti Nieminen, CEO of Biovian
We are delighted that ANLBIO has selected us as a partner for the process development and manufacturing of their AAV-based innovative drug candidate. Biovian has about two-decade-long history in developing and manufacturing viral vector processes, and we are happy to have a role in the journey of this novel molecule that holds the potential to help patients with Alzheimer’s disease. Thanks to MedClaris Inc, bio-consultancy for bringing Biovian and ANLBIO together.